Can carboplatin replace cisplatin for intraperitoneal use?

被引：10
作者：
Fujiwara, K. [1 ]
机构：
[1] Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, Hidaka City, Saitama 3501298, Japan
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2008年 / 18卷
关键词：
intraperitoneal chemotherapy; carboplatin; cisplatin; ovarian cancer;
D O I：
10.1111/j.1525-1438.2007.01101.x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Intraperitoneal (IP) chemotherapy is theoretically a feasible route for treating ovarian cancer. It is possible to expose tumor tissue disseminated peritoneal surface to extremely high concentration of anticancer agents. Three large-scale, randomized trials conducted in the US have demonstrated a significant improvement of progression survival and/or overall survival in IP chemotherapy arm over intravenous arm. Despite these favorable results, IP chemotherapy has not been accepted as standard care. One of the reasons for this is the use of cisplatin, which has been replaced by the less toxic platinum agent, carboplatin, when administered intravenously. In this review article, we discuss why IP chemotherapy using carboplatin has been ignored and its future potential.
引用
收藏
页码：29 / 32
页数：4
相关论文
共 11 条
  • [1] Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
    Bookman, MA
    McGuire, WP
    Kilpatrick, D
    Keenan, E
    Hogan, WM
    Johnson, SW
    ODwyer, P
    Rowinsky, E
    Gallion, HH
    Ozols, RF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1895 - 1902
  • [2] A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
    du Bois, A
    Lück, HJ
    Meier, W
    Adams, HP
    Möbus, V
    Costa, S
    Bauknecht, T
    Richter, B
    Warm, M
    Schröder, W
    Olbricht, S
    Nitz, U
    Jackisch, C
    Emons, G
    Wagner, U
    Kuhn, W
    Pfisterer, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17): : 1320 - 1330
  • [3] Principles and practice of intraperitoneal chemotherapy for ovarian cancer
    Fujiwara, K.
    Armstrong, D.
    Morgan, M.
    Markman, M.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (01) : 1 - 20
  • [4] Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube
    Fujiwara, K
    Suzuki, S
    Ishikawa, H
    Oda, T
    Aotani, E
    Kohno, I
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (03) : 426 - 431
  • [5] First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up
    Fujiwara, K
    Sakuragi, N
    Suzuki, S
    Yoshida, N
    Maehata, K
    Nishiya, M
    Koshida, T
    Sawai, H
    Aotani, E
    Kohno, I
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 90 (03) : 637 - 643
  • [6] PENETRATION OF CARBOPLATIN AND CISPLATIN INTO RAT PERITONEAL TUMOR NODULES AFTER INTRAPERITONEAL CHEMOTHERAPY
    LOS, G
    VERDEGAAL, EME
    MUTSAERS, PHA
    MCVIE, JG
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (03) : 159 - 165
  • [7] EVIDENCE SUPPORTING THE SUPERIORITY OF INTRAPERITONEAL CISPLATIN COMPARED TO INTRAPERITONEAL CARBOPLATIN FOR SALVAGE THERAPY OF SMALL-VOLUME RESIDUAL OVARIAN-CANCER
    MARKMAN, M
    REICHMAN, B
    HAKES, T
    RUBIN, S
    LEWIS, JL
    JONES, W
    BARAKAT, R
    CURTIN, J
    ALMADRONES, L
    HOSKINS, W
    [J]. GYNECOLOGIC ONCOLOGY, 1993, 50 (01) : 100 - 104
  • [8] A PHASE-II TRIAL OF INTRAPERITONEAL HIGH-DOSE CARBOPLATIN AND ETOPOSIDE WITH GRANULOCYTE MACROPHAGE-COLONY-STIMULATING FACTOR SUPPORT IN PATIENTS WITH OVARIAN-CARCINOMA
    MCCLAY, EF
    BRALY, PD
    KIRMANI, S
    PLAXE, SC
    KIM, S
    MCCLAY, ME
    WILGUS, L
    HOWELL, SB
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (01): : 23 - 26
  • [9] Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin - A Sankai Gynecology Study Group (SGSG) study
    Miyagi, Y
    Fujiwara, K
    Kigawa, J
    Itamochi, H
    Nagao, S
    Aotani, E
    Terakawa, N
    Kohno, I
    [J]. GYNECOLOGIC ONCOLOGY, 2005, 99 (03) : 591 - 596
  • [10] Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
    Ozols, RF
    Bundy, BN
    Greer, BE
    Fowler, JM
    Clarke-Pearson, D
    Burger, RA
    Mannel, RS
    DeGeest, K
    Hartenbach, EM
    Baergen, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3194 - 3200
12